Developer docs
API playgroundTry for free, no card

Search company profiles

Chirogate International

Full company profile

uuid0029bk2

Namestring
Chirogate International
Legal namestring
佳和桂科技股份有限公司 Chirogate International Inc.
Websiteurl
chirogate.com
Company typeenum
Private
Founded yearint
1999
Descriptiontext

Chirogate International Inc. (佳和桂科技股份有限公司) is a privately held specialty pharmaceutical manufacturer founded in 1999 and headquartered in Yangmei District, Taoyuan City, Taiwan. The company exclusively focuses on the development and manufacture of prostaglandin (PG) Active Pharmaceutical Ingredients (APIs), with a portfolio of over 20 commercial products including Latanoprost, Bimatoprost, Travoprost (glaucoma treatments), Treprostinil, Beraprost, Iloprost (pulmonary arterial hypertension), Misoprostol, Alprostadil, Dinoprostone, Carboprost, Lubiprostone, and veterinary Cloprostenol Sodium in various salt formulations.

Chirogate's core technology is a proprietary synthetic chemistry platform for prostaglandin manufacturing, employing novel organic synthesis and biochemical approaches that significantly reduce total synthetic steps and minimize stereo-isomer impurities in final products. The company has developed hundreds of novel PG intermediates and holds four US patents covering synthesis of PGF2α-related compounds and isomer-free prostaglandin processes. Manufacturing is conducted across four dedicated cGMP-compliant plants in the Taoyuan area (Youth/Wulin, Zhongli/ChungLi, Yangmei), each featuring independent production lines and HVAC systems to prevent cross-contamination. All facilities are designed to ICH and PIC/S guidelines, and the company has passed three US FDA inspections (2006, 2009, 2016), Japan PMDA inspection (2016), Mexico COFEPRIS inspection, and is certified as a US Pharmacopeia reference standard supplier.

The company operates a B2B enterprise sales model supplying prostaglandin APIs directly to global pharmaceutical companies, with over 90% of customers being foreign pharma firms in regulated markets (US, EU, Japan) and non-regulated markets worldwide. Pricing is quote-based and undisclosed, reflecting the high-value, small-volume nature of niche PG APIs. Revenue streams include direct API sales and custom synthesis services (process development, degradants, impurities, isomers, working standards, and metabolites synthesis). Active DMFs are maintained with US FDA (3 active), with additional filings across EU, Japan, Canada, China, Australia, and New Zealand, enabling global product distribution.

Short descriptiontext

Chirogate International is a Taiwan-based specialty pharmaceutical manufacturer founded in 1999 that exclusively develops and produces prostaglandin Active Pharmaceutical Ingredients (APIs), supplying over 20 commercial products to global pharmaceutical companies with over 90% of customers being foreign pharma firms in regulated and non-regulated markets.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersTaoyüan, Taiwan
HQ citystring
Taoyüan
HQ countrystring
Taiwan
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
prostaglandin APIs, active pharmaceutical ingredients, custom synthesis services, cGMP API manufacturing, pharmaceutical intermediates
Industry4 codes
PRIMARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAJADAI
Regulatory Affairs, Labeling & Advertising/Promotion Compliance
Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Pharmaceutical Preparation Manufacturing325412
SIC code3 codes
  • Medicinal Chemicals & Botanical Products2833
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Active Pharmaceutical Ingredients (APIs)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Active Pharmaceutical Ingredient (API) Sales
TypeOne Time License
Description

Manufacture and sale of prostaglandin Active Pharmaceutical Ingredients to pharmaceutical companies worldwide. Products are described as small-volume, high-price niche products with high added value and pharmacological activity.

chirogate.com
2Custom Synthesis Services
TypeProfessional Services
Description

Custom manufacturing services for prostaglandins including custom synthesis, process development, degradants synthesis, impurities synthesis, isomers synthesis, working standards synthesis, and metabolites synthesis.

chirogate.com
Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Chirogate International is a specialty pharmaceutical manufacturer that produces and globally supplies prostaglandin Active Pharmaceutical Ingredients (APIs) such as Latanoprost, Bimatoprost, Travoprost, Treprostinil, Misoprostol, Alprostadil, and Dinoprostone to pharmaceutical companies worldwide. The company also provides custom synthesis, process development, and reference standard manufacturing services. Over 90% of customers are foreign pharmaceutical firms, and all products are manufactured in cGMP-compliant facilities following ICH and PIC/S guidelines.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Successfully commercialized over 10 prostaglandin products
+2 more records
Product overview1 text field

Chirogate International is a specialty pharmaceutical manufacturer focused exclusively on prostaglandin (PG) Active Pharmaceutical Ingredients (APIs). The company offers a portfolio of over 20 commercial-scale prostaglandin products including Treprostinil, Beraprost, Iloprost, Latanoprost, Bimatoprost, Travoprost, Tafluprost, Misoprostol, Lubiprostone, Dinoprost, Alprostadil, Dinoprostone, and Cloprostenol Sodium in various formulations (base, sodium salts, tromethamine salts). Additionally, the company provides contract manufacturing services including custom synthesis, process development, and synthesis of degradants, impurities, isomers, working standards, and metabolites. All products are manufactured in cGMP-compliant facilities with dedicated production lines for each product to prevent cross-contamination.

Product and service17 records
1Latanoprost
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin F2α analog Active Pharmaceutical Ingredient used by pharmaceutical manufacturers for glaucoma and ocular hypertension treatments.

2Bimatoprost
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin analog API used by pharmaceutical companies for glaucoma treatment and eyelash growth formulations.

3Travoprost
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin F2α analog API used in finished drugs for glaucoma and ocular hypertension treatment.

4Treprostinil (and Treprostinil Sodium, Treprostinil Diethanolamine)
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin analog API supplied in base, sodium salt, and diethanolamine salt forms for vasodilator applications including pulmonary arterial hypertension treatment.

5Beraprost Sodium (and Beraprost-314d)
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin I2 analog API used as a vasodilator and antiplatelet agent, including an extended-acting formulation (Beraprost-314d).

6Iloprost (and Iloprost Tromethamine)
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin analog API used in finished drugs for pulmonary arterial hypertension and peripheral vascular disease, available as base and tromethamine salt.

7Carboprost (and Carboprost Tromethamine)
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin F2α analog API used as a uterotonic agent for treatment of postpartum hemorrhage, supplied as base and tromethamine salt.

8Misoprostol (and Misoprostol 1% HPMC)
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin E1 analog API used by pharmaceutical manufacturers for gastric ulcer prevention and labor induction, including an HPMC formulation variant.

9Alprostadil
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin E1 API used in finished drugs for erectile dysfunction and peripheral vascular disease treatment.

10Dinoprostone
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin E2 API used in finished drugs for labor induction and cervical ripening.

11Dinoprost / PGF2α (and Dinoprost Tromethamine)
CategoryActive Pharmaceutical Ingredient
Description

Natural prostaglandin F2α API supplied as base and tromethamine salt for labor induction and veterinary applications.

12Latanoprostene Bunod
CategoryActive Pharmaceutical Ingredient
Description

Nitric oxide-donating prostaglandin analog API used by pharmaceutical companies for glaucoma treatment formulations.

13Unoprostone Isopropyl
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin F2α analog API used in finished drugs for glaucoma treatment.

14Tafluprost
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin analog API used by pharmaceutical manufacturers for glaucoma and ocular hypertension formulations.

15Lubiprostone
CategoryActive Pharmaceutical Ingredient
Description

Prostaglandin E1 derivative API used in finished drugs for chronic constipation treatment.

16Cloprostenol Sodium
CategoryActive Pharmaceutical Ingredient
Description

Synthetic prostaglandin F2α analog API supplied to veterinary pharmaceutical manufacturers.

17Custom Synthesis & Contract Manufacturing Services
CategoryCustom Manufacturing Service
Description

Bespoke contract manufacturing services including custom synthesis, process development, degradants synthesis, impurities synthesis, isomers synthesis, working standards synthesis, and metabolites synthesis for prostaglandin-related compounds. Services are tailored to pharmaceutical customer specifications for research, development, and quality control applications.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move14 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Canadian specialty chemical manufacturer producing prostaglandin intermediates, impurities, metabolites, and reference standards. Closely comparable in custom synthesis and chiral prostaglandin chemistry services for the pharmaceutical industry.

TypeDirect peer
Description

US-based manufacturer of prostaglandins, eicosanoids, and related bioactive lipids for research and pharmaceutical use. Directly comparable as a prostaglandin-focused specialty API/reagent manufacturer with similar customer overlap in pharma R&D and reference-standards supply.

TypeEmerging player
Description

China-headquartered CRO/CDMO with API manufacturing capabilities including custom synthesis and small-molecule API supply. Comparable as a chemistry-focused CDMO competing in the custom synthesis and API manufacturing space, particularly in Asia.

TypeBroad incumbent
Description

Indian listed API manufacturer producing prostaglandin APIs (including Latanoprost) and other complex generic APIs at scale. Comparable as a global prostaglandin API supplier competing in the same molecule categories as Chirogate with a cost-advantaged footprint.

TypeDirect peer
Description

Swiss-headquartered contract manufacturer of peptides and small-molecule APIs for the pharmaceutical industry. Comparable as a privately held, technology-driven CDMO serving global pharma with a focus on complex, high-purity API manufacturing.

TypeBroad incumbent
Description

UK-based specialty chemicals company with a pharmaceutical API and custom synthesis business including prostaglandin chemistry. Comparable as a long-established, multi-site cGMP API manufacturer serving global pharma with chiral synthesis expertise.

TypeDirect peer
Description

Swiss API development and manufacturing organization (part of Dishman Carbogen Amcis) with strong capabilities in chiral chemistry and prostaglandin synthesis. Directly comparable as a CDMO serving regulated pharmaceutical markets with complex small-molecule APIs.

TypeBroad incumbent
Description

Swiss-listed CDMO specializing in peptide and oligonucleotide APIs, also offering prostaglandin-related custom synthesis. Comparable as a high-quality, cGMP-compliant API manufacturer with global regulatory inspection history and pharma customer base.

TypeBroad incumbent
Description

Finnish API manufacturer producing generic APIs and intermediates, including prostaglandin and complex chiral molecules. Comparable as a cGMP-compliant API manufacturer with global DMF presence supplying regulated pharmaceutical markets.

TypeBroad incumbent
Description

European CDMO offering custom synthesis and manufacturing of complex APIs, including prostaglandin-related molecules. Comparable as a cGMP API manufacturer with strong chiral chemistry expertise serving global pharmaceutical customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Chirogate International

Active Pharmaceutical Ingredients (APIs)chirogate.com

Chirogate International is a Taiwan-based specialty pharmaceutical manufacturer founded in 1999 that exclusively develops and produces prostaglandin Active Pharmaceutical Ingredients (APIs), supplying over 20 commercial products to global pharmaceutical companies with over 90% of customers being foreign pharma firms in regulated and non-regulated markets.

What Chirogate International does

Chirogate International Inc. (佳和桂科技股份有限公司) is a privately held specialty pharmaceutical manufacturer founded in 1999 and headquartered in Yangmei District, Taoyuan City, Taiwan. The company exclusively focuses on the development and manufacture of prostaglandin (PG) Active Pharmaceutical Ingredients (APIs), with a portfolio of over 20 commercial products including Latanoprost, Bimatoprost, Travoprost (glaucoma treatments), Treprostinil, Beraprost, Iloprost (pulmonary arterial hypertension), Misoprostol, Alprostadil, Dinoprostone, Carboprost, Lubiprostone, and veterinary Cloprostenol Sodium in various salt formulations.

Chirogate's core technology is a proprietary synthetic chemistry platform for prostaglandin manufacturing, employing novel organic synthesis and biochemical approaches that significantly reduce total synthetic steps and minimize stereo-isomer impurities in final products. The company has developed hundreds of novel PG intermediates and holds four US patents covering synthesis of PGF2α-related compounds and isomer-free prostaglandin processes. Manufacturing is conducted across four dedicated cGMP-compliant plants in the Taoyuan area (Youth/Wulin, Zhongli/ChungLi, Yangmei), each featuring independent production lines and HVAC systems to prevent cross-contamination. All facilities are designed to ICH and PIC/S guidelines, and the company has passed three US FDA inspections (2006, 2009, 2016), Japan PMDA inspection (2016), Mexico COFEPRIS inspection, and is certified as a US Pharmacopeia reference standard supplier.

The company operates a B2B enterprise sales model supplying prostaglandin APIs directly to global pharmaceutical companies, with over 90% of customers being foreign pharma firms in regulated markets (US, EU, Japan) and non-regulated markets worldwide. Pricing is quote-based and undisclosed, reflecting the high-value, small-volume nature of niche PG APIs. Revenue streams include direct API sales and custom synthesis services (process development, degradants, impurities, isomers, working standards, and metabolites synthesis). Active DMFs are maintained with US FDA (3 active), with additional filings across EU, Japan, Canada, China, Australia, and New Zealand, enabling global product distribution.

Chirogate International firmographics

Firmographics
Name
Chirogate International
Legal name
佳和桂科技股份有限公司 Chirogate International Inc.
Website
https://chirogate.com
Company type
Private
Founded year
1999
Operating status
Operating
Headcount range
1–10 employees
Short description
Chirogate International is a Taiwan-based specialty pharmaceutical manufacturer founded in 1999 that exclusively develops and produces prostaglandin Active Pharmaceutical Ingredients (APIs), supplying over 20 commercial products to global pharmaceutical companies with over 90% of customers being foreign pharma firms in regulated and non-regulated markets.
Ownership category
akta.pro rank

Chirogate International industry classification

Industry
Product category
Active Pharmaceutical Ingredients (APIs)
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)
SIC
Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAA
Small-Molecule Generics (Branded/Unbranded)
SECONDARYHLAJADAI
Regulatory Affairs, Labeling & Advertising/Promotion Compliance
Healthcare & Life Sciences/Public Health, Government & Regulators/Medicines & Healthcare Product Regulators (Drugs/Biologics/Devices)

Keywords

  • Prostaglandin APIs
  • Active pharmaceutical ingredients
  • Custom synthesis services
  • CGMP API manufacturing
  • Pharmaceutical intermediates

Where Chirogate International is headquartered

Location

Headquarters

HQ city
Taoyüan
HQ country
Taiwan
HQ region
Asia

Offices2 records

Markets served

Chirogate International business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Technology or R&D, Infrastructure, Supply Chain

Revenue model

  1. Active Pharmaceutical Ingredient (API) Sales: Manufacture and sale of prostaglandin Active Pharmaceutical Ingredients to pharmaceutical companies worldwide. Products are described as small-volume, high-price niche products with high added value and pharmacological activity.
  2. Custom Synthesis Services: Custom manufacturing services for prostaglandins including custom synthesis, process development, degradants synthesis, impurities synthesis, isomers synthesis, working standards synthesis, and metabolites synthesis.

Go-to-market motion1 record

Distribution channels1 record

Chirogate International product offering

Product offering

Core offering

Chirogate International is a specialty pharmaceutical manufacturer that produces and globally supplies prostaglandin Active Pharmaceutical Ingredients (APIs) such as Latanoprost, Bimatoprost, Travoprost, Treprostinil, Misoprostol, Alprostadil, and Dinoprostone to pharmaceutical companies worldwide. The company also provides custom synthesis, process development, and reference standard manufacturing services. Over 90% of customers are foreign pharmaceutical firms, and all products are manufactured in cGMP-compliant facilities following ICH and PIC/S guidelines.

Product overview

Chirogate International is a specialty pharmaceutical manufacturer focused exclusively on prostaglandin (PG) Active Pharmaceutical Ingredients (APIs). The company offers a portfolio of over 20 commercial-scale prostaglandin products including Treprostinil, Beraprost, Iloprost, Latanoprost, Bimatoprost, Travoprost, Tafluprost, Misoprostol, Lubiprostone, Dinoprost, Alprostadil, Dinoprostone, and Cloprostenol Sodium in various formulations (base, sodium salts, tromethamine salts). Additionally, the company provides contract manufacturing services including custom synthesis, process development, and synthesis of degradants, impurities, isomers, working standards, and metabolites. All products are manufactured in cGMP-compliant facilities with dedicated production lines for each product to prevent cross-contamination.

Differentiator

Problem solved

Functional benefit

Products and services

  • Latanoprost Prostaglandin F2α analog Active Pharmaceutical Ingredient used by pharmaceutical manufacturers for glaucoma and ocular hypertension treatments.
  • Bimatoprost Prostaglandin analog API used by pharmaceutical companies for glaucoma treatment and eyelash growth formulations.
  • Travoprost Prostaglandin F2α analog API used in finished drugs for glaucoma and ocular hypertension treatment.
  • Treprostinil (and Treprostinil Sodium, Treprostinil Diethanolamine) Prostaglandin analog API supplied in base, sodium salt, and diethanolamine salt forms for vasodilator applications including pulmonary arterial hypertension treatment.
  • Beraprost Sodium (and Beraprost-314d) Prostaglandin I2 analog API used as a vasodilator and antiplatelet agent, including an extended-acting formulation (Beraprost-314d).
  • Iloprost (and Iloprost Tromethamine) Prostaglandin analog API used in finished drugs for pulmonary arterial hypertension and peripheral vascular disease, available as base and tromethamine salt.
  • Carboprost (and Carboprost Tromethamine) Prostaglandin F2α analog API used as a uterotonic agent for treatment of postpartum hemorrhage, supplied as base and tromethamine salt.
  • Misoprostol (and Misoprostol 1% HPMC) Prostaglandin E1 analog API used by pharmaceutical manufacturers for gastric ulcer prevention and labor induction, including an HPMC formulation variant.
  • Alprostadil Prostaglandin E1 API used in finished drugs for erectile dysfunction and peripheral vascular disease treatment.
  • Dinoprostone Prostaglandin E2 API used in finished drugs for labor induction and cervical ripening.
  • Dinoprost / PGF2α (and Dinoprost Tromethamine) Natural prostaglandin F2α API supplied as base and tromethamine salt for labor induction and veterinary applications.
  • Latanoprostene Bunod Nitric oxide-donating prostaglandin analog API used by pharmaceutical companies for glaucoma treatment formulations.
  • Unoprostone Isopropyl Prostaglandin F2α analog API used in finished drugs for glaucoma treatment.
  • Tafluprost Prostaglandin analog API used by pharmaceutical manufacturers for glaucoma and ocular hypertension formulations.
  • Lubiprostone Prostaglandin E1 derivative API used in finished drugs for chronic constipation treatment.
  • Cloprostenol Sodium Synthetic prostaglandin F2α analog API supplied to veterinary pharmaceutical manufacturers.
  • Custom Synthesis & Contract Manufacturing Services Bespoke contract manufacturing services including custom synthesis, process development, degradants synthesis, impurities synthesis, isomers synthesis, working standards synthesis, and metabolites synthesis for prostaglandin-related compounds. Services are tailored to pharmaceutical customer specifications for research, development, and quality control applications.

Quantifiable outcome

  • Successfully commercialized over 10 prostaglandin products
  • +2 more outcomes

Companies that use Chirogate International

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Chirogate International technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Chirogate International partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves14 records

Expansion highlights6 records

Chirogate International competitors and assessment

Company assessment

Direct peers

  • Toronto Research Chemicals: Canadian specialty chemical manufacturer producing prostaglandin intermediates, impurities, metabolites, and reference standards. Closely comparable in custom synthesis and chiral prostaglandin chemistry services for the pharmaceutical industry.
  • Cayman Chemical: US-based manufacturer of prostaglandins, eicosanoids, and related bioactive lipids for research and pharmaceutical use. Directly comparable as a prostaglandin-focused specialty API/reagent manufacturer with similar customer overlap in pharma R&D and reference-standards supply.
  • Polypeptide Laboratories (PolyPeptide Group): Swiss-headquartered contract manufacturer of peptides and small-molecule APIs for the pharmaceutical industry. Comparable as a privately held, technology-driven CDMO serving global pharma with a focus on complex, high-purity API manufacturing.
  • Carbogen Amcis: Swiss API development and manufacturing organization (part of Dishman Carbogen Amcis) with strong capabilities in chiral chemistry and prostaglandin synthesis. Directly comparable as a CDMO serving regulated pharmaceutical markets with complex small-molecule APIs.

Emerging players

  • ChemPartner: China-headquartered CRO/CDMO with API manufacturing capabilities including custom synthesis and small-molecule API supply. Comparable as a chemistry-focused CDMO competing in the custom synthesis and API manufacturing space, particularly in Asia.

Broad incumbents

  • Divis Laboratories: Indian listed API manufacturer producing prostaglandin APIs (including Latanoprost) and other complex generic APIs at scale. Comparable as a global prostaglandin API supplier competing in the same molecule categories as Chirogate with a cost-advantaged footprint.
  • Johnson Matthey (Pharma Services / Macfarlan Smith): UK-based specialty chemicals company with a pharmaceutical API and custom synthesis business including prostaglandin chemistry. Comparable as a long-established, multi-site cGMP API manufacturer serving global pharma with chiral synthesis expertise.
  • Bachem: Swiss-listed CDMO specializing in peptide and oligonucleotide APIs, also offering prostaglandin-related custom synthesis. Comparable as a high-quality, cGMP-compliant API manufacturer with global regulatory inspection history and pharma customer base.
  • Fermion (subsidiary of Orion Corporation): Finnish API manufacturer producing generic APIs and intermediates, including prostaglandin and complex chiral molecules. Comparable as a cGMP-compliant API manufacturer with global DMF presence supplying regulated pharmaceutical markets.
  • Axplora (formerly Novasep Pharma Solutions): European CDMO offering custom synthesis and manufacturing of complex APIs, including prostaglandin-related molecules. Comparable as a cGMP API manufacturer with strong chiral chemistry expertise serving global pharmaceutical customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Chirogate International social profiles

Digital presence

Chirogate International compliance and trust

Trust signal

Compliance7 records

Chirogate International financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Chirogate International leadership team

Management profile

Number of profiles

Chirogate International funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Chirogate International M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chirogate International

What does Chirogate International do?

Chirogate International is a specialty pharmaceutical manufacturer that produces and globally supplies prostaglandin Active Pharmaceutical Ingredients (APIs) such as Latanoprost, Bimatoprost, Travoprost, Treprostinil, Misoprostol, Alprostadil, and Dinoprostone to pharmaceutical companies worldwide. The company also provides custom synthesis, process development, and reference standard manufacturing services. Over 90% of customers are foreign pharmaceutical firms, and all products are manufactured in cGMP-compliant facilities following ICH and PIC/S guidelines.

Is Chirogate International a public or private company?

Chirogate International is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Chirogate International founded?

Chirogate International was founded in 1999. It employs 1 to 10 people.

Where is Chirogate International based?

Chirogate International is headquartered in Taoyüan, Taiwan, in the Asia region.

How does Chirogate International make money?

Two revenue lines are on record. Active Pharmaceutical Ingredient (API) Sales are the primary driver. The others are custom Synthesis Services.

Who are Chirogate International's main competitors?

Direct peers on record are Toronto Research Chemicals, Cayman Chemical, Polypeptide Laboratories (PolyPeptide Group) and Carbogen Amcis. ChemPartner is listed as an emerging player. Broad incumbents are Divis Laboratories, Johnson Matthey (Pharma Services / Macfarlan Smith), Bachem, Fermion (subsidiary of Orion Corporation) and Axplora (formerly Novasep Pharma Solutions).

Does Chirogate International have an API?

No public API is recorded for Chirogate International.

What industry is Chirogate International in?

Chirogate International's product category is Active Pharmaceutical Ingredients (APIs). Its primary akta.pro industry code is HLAGAHAB, Small-Molecule API Commercial Manufacturing, with a secondary code of HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 3254 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales